138 related articles for article (PubMed ID: 30874432)
1. Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity In Vitro and In Vivo.
Francini N; Cochrane D; Illingworth S; Purdie L; Mantovani G; Fisher K; Seymour LW; Spain SG; Alexander C
Bioconjug Chem; 2019 Apr; 30(4):1244-1257. PubMed ID: 30874432
[TBL] [Abstract][Full Text] [Related]
2. Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses.
Brugada-Vilà P; Cascante A; Lázaro MÁ; Castells-Sala C; Fornaguera C; Rovira-Rigau M; Albertazzi L; Borros S; Fillat C
Theranostics; 2020; 10(6):2744-2758. PubMed ID: 32194832
[TBL] [Abstract][Full Text] [Related]
3. Poly-Gamma-Glutamic Acid (γ-PGA)-Based Encapsulation of Adenovirus to Evade Neutralizing Antibodies.
Khalil IR; Khechara MP; Kurusamy S; Armesilla AL; Gupta A; Mendrek B; Khalaf T; Scandola M; Focarete ML; Kowalczuk M; Radecka I
Molecules; 2018 Oct; 23(10):. PubMed ID: 30297641
[TBL] [Abstract][Full Text] [Related]
4. Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.
Lei J; Jacobus EJ; Taverner WK; Fisher KD; Hemmi S; West K; Slater L; Lilley F; Brown A; Champion B; Duffy MR; Seymour LW
J Immunother Cancer; 2018 Jun; 6(1):55. PubMed ID: 29898782
[TBL] [Abstract][Full Text] [Related]
5. HPMA copolymers for masking and retargeting of therapeutic viruses.
Fisher KD; Seymour LW
Adv Drug Deliv Rev; 2010 Feb; 62(2):240-5. PubMed ID: 20005911
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex.
Kim J; Li Y; Kim SW; Lee DS; Yun CO
Biomaterials; 2013 Jun; 34(19):4622-31. PubMed ID: 23541109
[TBL] [Abstract][Full Text] [Related]
7. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.
Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C
J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11.
Mato-Berciano A; Morgado S; Maliandi MV; Farrera-Sal M; Gimenez-Alejandre M; Ginestà MM; Moreno R; Torres-Manjon S; Moreno P; Arias-Badia M; Rojas LA; Capellà G; Alemany R; Cascallo M; Bazan-Peregrino M
J Control Release; 2021 Apr; 332():517-528. PubMed ID: 33675877
[TBL] [Abstract][Full Text] [Related]
9. Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer.
Kim J; Nam HY; Choi JW; Yun CO; Kim SW
Gene Ther; 2014 May; 21(5):476-83. PubMed ID: 24598892
[TBL] [Abstract][Full Text] [Related]
10. Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy.
Lv P; Liu X; Chen X; Liu C; Zhang Y; Chu C; Wang J; Wang X; Chen X; Liu G
Nano Lett; 2019 May; 19(5):2993-3001. PubMed ID: 30964695
[TBL] [Abstract][Full Text] [Related]
11. Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery.
Rojas LA; Condezo GN; Moreno R; Fajardo CA; Arias-Badia M; San Martín C; Alemany R
J Control Release; 2016 Sep; 237():78-88. PubMed ID: 27388756
[TBL] [Abstract][Full Text] [Related]
12. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.
Fisher KD; Stallwood Y; Green NK; Ulbrich K; Mautner V; Seymour LW
Gene Ther; 2001 Mar; 8(5):341-8. PubMed ID: 11313809
[TBL] [Abstract][Full Text] [Related]
13. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.
Niemann J; Woller N; Brooks J; Fleischmann-Mundt B; Martin NT; Kloos A; Knocke S; Ernst AM; Manns MP; Kubicka S; Wirth TC; Gerardy-Schahn R; Kühnel F
Nat Commun; 2019 Jul; 10(1):3236. PubMed ID: 31324774
[TBL] [Abstract][Full Text] [Related]
14. Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.
Marino N; Illingworth S; Kodialbail P; Patel A; Calderon H; Lear R; Fisher KD; Champion BR; Brown ACN
PLoS One; 2017; 12(5):e0177810. PubMed ID: 28542292
[TBL] [Abstract][Full Text] [Related]
15. Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration.
Choi JW; Dayananda K; Jung SJ; Lee SH; Kim D; Hu J; Bae YH; Yun CO
Acta Biomater; 2015 Dec; 28():86-98. PubMed ID: 26365317
[TBL] [Abstract][Full Text] [Related]
16. Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses.
Thambi T; Hong J; Yoon AR; Yun CO
Cancer Gene Ther; 2022 Oct; 29(10):1321-1331. PubMed ID: 35444290
[TBL] [Abstract][Full Text] [Related]
17. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
Green NK; Morrison J; Hale S; Briggs SS; Stevenson M; Subr V; Ulbrich K; Chandler L; Mautner V; Seymour LW; Fisher KD
J Gene Med; 2008 Mar; 10(3):280-9. PubMed ID: 18214996
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus.
Kasala D; Lee SH; Hong JW; Choi JW; Nam K; Chung YH; Kim SW; Yun CO
Biomaterials; 2017 Nov; 145():207-222. PubMed ID: 28869866
[TBL] [Abstract][Full Text] [Related]
19. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.
Koski A; Raki M; Nokisalmi P; Liikanen I; Kangasniemi L; Joensuu T; Kanerva A; Pesonen S; Alemany R; Hemminki A
Mol Ther; 2012 Jan; 20(1):221-9. PubMed ID: 22044933
[TBL] [Abstract][Full Text] [Related]
20. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.
Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y
Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
